FDA Releases CMC Postapproval Manufacturing Changes For Specified Biological Products To Be Documented In Annual Reports

This new FDA/CDER guidance represents the FDA's thinking regarding the types of changes to an approved biologics license application (BLA) that...

Related Keywords

Mark Durivage ,Office Of Communication ,International Council For Harmonisation ,Office Of Pharmaceutical Quality ,Quality Systems Compliance ,Drug Evaluation ,Biologics Evaluation ,Manufacturing Changes ,Specified Biological Products To Be Documented ,Annual Reports ,International Council ,Manufacturing Practice Guidance ,Active Pharmaceutical Ingredients ,Risk Management ,Quality System ,Federal Food ,Cosmetic Act ,Approval Supplement Expedited Review Requested ,Changes That ,Considers Having ,Approved Application ,Specified Biotechnology ,Specified Synthetic Biological Products ,Pharmaceutical Quality ,